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A B S T R A C T
The treatment of post-surgical meningitis due tomultidrug-resistant (MDR) Acinetobacter baumannii is a
therapeutic dilemma. The cases of two patients with MDR A. baumanniimeningitis secondary to surgical
site infections, successfully treated with combination regimens including tigecycline, are presented.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acinetobacter baumannii is an aerobic, non-fermentative,
oxidase-negative, Gram-negative coccobacillus that is ubiquitous
in the environment.1 Although the isolation of these organisms
from clinical specimensmay result from colonization, A. baumannii
has potential to cause a wide spectrum of nosocomial infections
such as pneumonia, bacteremia, urinary tract infections, and
meningitis.1,2 A. baumannii meningitis in post-neurosurgical
patients and outbreaks following neurosurgical procedures have
been reported.2–4 The emergence of multidrug resistance in
Acinetobacter isolates may pose a signiﬁcant problem in nosoco-
mial infections.
We report two cases of multidrug-resistant (MDR) A. baumannii
meningitis secondary to surgical site infections following neuro-
surgical procedures, treated with combination regimens including
tigecycline.
2. Case reports
2.1. Case 1
A 48-year-old male underwent surgery following a car accident
and had spinal instrumentation due to a T6 vertebral fracture. He* Corresponding author. Tel.: +90 532 511 5000; fax: +90 312 318 6690.
E-mail address: ediztutuncu@gmail.com (E.E. Tutuncu).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.022was discharged after the surgery but returned to the emergency
service a week later with headache, backache, and discharge from
his surgical wound. On admission hewas conscious and had a fever
of 39 8C. Physical examination revealed neck stiffness and a
purulent discharge from the surgical site. He had a marked
leukocytosis (32.4  109/l); biochemical parameters were within
normal limits.
A lumbar puncture was performed. Cerebrospinal ﬂuid (CSF)
examination revealed awhite blood cell count of 1350  106/l (95%
polymorphonuclear leukocytes), glucose of 10 mg/dl, and total
protein of 552 mg/dl; a simultaneous blood glucose was 72 mg/dl.
After obtaining surgical site discharge, CSF, and blood cultures,
vancomycin 2  1 g/day IV and meropenem 3  2 g/day IV were
initiated empirically.
On the following day, cultures of surgical site discharge and CSF
grew A. baumannii. Netilmicin 1  400 mg/day IV was added to the
empirical regimen pending susceptibility testing results in
accordance with our local surveillance ﬁndings. On the third
day, it was shown that both isolates had the same susceptibility
pattern and were only susceptible to tigecycline and netilmicin by
the disk diffusion method. The minimum inhibitory concentration
(MIC) for tigecycline was 0.38mg/ml by Etest (AB Biodisk, Solna,
Sweden). The patient was still febrile; vancomycin was discon-
tinued and tigecycline was added at 50 mg every 12 h following a
loading dose of 100 mg.
After the new combination therapy, the patient’s temperature
returned to normal and the surgical site discharge was reduced.
Netilmicin was continued for two weeks and meropenem andses. Published by Elsevier Ltd. All rights reserved.
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week the patient had no evidence of surgical site infection or
meningitis and was discharged from the hospital without any
sequelae.
2.2. Case 2
A52-year-oldmanhad undergone surgery twice in the previous
two months for lumbar disk herniation at the L2–L3 level. Four
days after the second surgical intervention, he was diagnosed with
a surgical site infection by his surgeon. Local wound carewas taken
and no systemic antibiotics were applied.
On the eighth day his condition had deteriorated. On physical
examination, neck stiffness, unconsciousness, and fever were
noted. CSF obtained via lumbar puncture showed 1930  106/l
white blood cells (95% polymorphonuclear leukocytes), glucose of
29 mg/dl, and total protein of 136 mg/dl; a simultaneous blood
glucose level was 177 mg/dl. Following CSF and blood cultures,
vancomycin 2  1 g/day IV and meropenem 3  2 g/day IV were
initiated empirically with the diagnosis of post-neurosurgical
meningitis.
On the second day, CSF culture yielded A. baumannii. Netilmicin
1  400 mg/day IV was added to the empirical regimen. The
following day, the isolate was found to be MDR by the disk
diffusion method and it was only sensitive to tigecycline and
netilmicin. The MIC for tigecycline was 0.38mg/ml by Etest (AB
Biodisk). Vancomycin was stopped and tigecycline 2  50 mg/day
IV, following a loading dose of 100 mg IV, was added to the
combination therapy.
At follow-up, the patient’smental status improved and his fever
gradually subsided. Netilmicin was stopped at the end of the
second week and meropenem and tigecycline were continued for
three weeks. The patient was discharged at the end of therapy
without any evidence of infection.
3. Discussion
Nosocomial meningitis following neurosurgical procedures is
relatively uncommon.5,6 The epidemiology of post-neurosurgical
meningitis has changed in the last decade and Gram-negative
bacillary meningitis has become increasingly important.7,8 The
emergence ofMDR strains in recent years has complicated therapy.
As a consequence, carbapenems have been recommended as part
of the initial choice of empirical therapy for post-neurosurgical
meningitis.7,9
A. baumannii rarely causes community-acquired infections.
Invasive neurosurgical procedures constitute one of the major risk
factors for Acinetobacter spp meningitis. Krol et al. reviewed the
literature recently and reported that almost all A. baumannii
meningitis reports since 1962 have been related to invasive
procedures such as craniotomy or ventriculostomy.2 Deep and
superﬁcial surgical site infections have also been reported to cause
nosocomial meningitis.6
A. baumannii is characterized by frequent multidrug resistance.
Carbapenems have been regarded as the agents of choice for A.
baumannii infections for a long time, but resistance rates have risen
substantially in some areas.10 The carbapenem susceptibility of
Acinetobacter isolates in patients with nosocomial meningitis was
found to be only 55% in the study by Metan et al.7 The high
incidence of carbapenem-resistant strains narrows the therapeutic
options and complicates empirical therapy.
Colistin is one of the few alternatives for treating MDR A.
baumannii infections. There are numerous reports regarding the
use of intravenous and intrathecal colistin for MDR A. baumannii
meningitis.11,12 The use of colistin in Turkey is hindered by the
unavailability of this drug in themarket. On the other hand, clinicalexperiences with the use of sulbactam for treating MDR A.
baumannii meningitis are limited and rather inconclusive.10
Tigecycline is the ﬁrst commercially available agent of a new
class of antimicrobials, the glycylcyclines. It has been licensed for
the treatment of complicated intra-abdominal infections and
complicated skin and skin structure infections. It has been shown
to have good in vitro activity against carbapenem-resistant A.
baumannii isolates.13 A comprehensive review by Karageorgopou-
los et al. provides information regarding the use of tigecycline in
various clinical conditions, such as ventilator-associated pneumo-
nia, bacteremia and urinary tract infections due to MDR A.
baumannii. Tigecycline has been used mainly as part of a
combination regimen for the treatment of these infections and
most patients included in these reports had good clinical
outcomes.14
However clinical experience in patients with meningitis is very
limited. There is one case report regarding the use of tigecycline in
a patient with meningitis secondary to an external shunt
infection.15 In addition, a review of 34 patients by Gordon and
Wareham included a patient who had A. baumannii meningitis
treated with tigecycline and had a favorable clinical response.16
Also, in a rabbit model of penicillin-resistant pneumococcal
meningitis, tigecycline was found to be effective in reducing
colony counts in CSF in combination with vancomycin.17
Herein, we have reported two cases of MDR A. baumannii
meningitis secondary to surgical site infections. Both patients had
surgical site infections following neurosurgical procedures and
consequently developed meningitis. The diagnosis was based on
clinical and CSF ﬁndings, as well as positive CSF cultures. Both A.
baumannii isolates recovered from the CSF of these patients were
resistant to carbapenems, piperacillin/tazobactam, ceftazidime,
and quinolones and showed susceptibility only to tigecycline and
netilmicin.
Although tigecycline is not approved for central nervous system
infections, it was the best available option for the treatment of
these two cases according to the antibiotic susceptibility results.
Considering the information available regarding the enhanced
therapeutic effect that might result from the use of tigecycline in
combination with other agents, even in cases of resistance to other
antibiotics, meropenem was not discontinued.18 The clinical
condition of both patients improved only after tigecycline was
added to the regimen.
In conclusion, MDR A. baumannii meningitis is a rare
complication of neurosurgical procedures. Treatment of these
infections is a challenge for physicians and experience is limited.
Central nervous system infections due to MDR A. baumannii will
not respond to empirical treatment and special attention must be
given in accordance with the local surveillance ﬁndings in
hospitals where A. baumannii is prevalent.
To the best of our knowledge, this is the ﬁrst report of
tigecycline therapy in combination with meropenem and netilmi-
cin for MDR A. baumannii meningitis secondary to surgical site
infections. Further research is necessary to determine the role of
tigecycline in the treatment of MDR A. baumannii infections.
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